- Home
- ADPT vs GLPG Comparison
ADPT vs GLPG Comparison
Compare ADPT & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- GLPG
- Stock Information
- Founded
- ADPT 2009
- GLPG 1999
- Country
- ADPT United States
- GLPG Belgium
- Employees
- ADPT N/A
- GLPG N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- ADPT Health Care
- GLPG Health Care
- Exchange
- ADPT Nasdaq
- GLPG Nasdaq
- Market Cap
- ADPT 2.0B
- GLPG 2.1B
- IPO Year
- ADPT 2019
- GLPG 2005
- Fundamental
- Price
- ADPT $15.53
- GLPG N/A
- Analyst Decision
- ADPT Strong Buy
- GLPG Sell
- Analyst Count
- ADPT 10
- GLPG 3
- Target Price
- ADPT $13.60
- GLPG $26.00
- AVG Volume (30 Days)
- ADPT 2.0M
- GLPG 215.3K
- Earning Date
- ADPT 11-06-2025
- GLPG 10-29-2025
- Dividend Yield
- ADPT N/A
- GLPG N/A
- EPS Growth
- ADPT N/A
- GLPG N/A
- EPS
- ADPT N/A
- GLPG N/A
- Revenue
- ADPT $205,216,000.00
- GLPG $323,674,692.00
- Revenue This Year
- ADPT $32.63
- GLPG $1.77
- Revenue Next Year
- ADPT $16.31
- GLPG $0.44
- P/E Ratio
- ADPT N/A
- GLPG N/A
- Revenue Growth
- ADPT 21.60
- GLPG 5.43
- 52 Week Low
- ADPT $4.27
- GLPG $22.36
- 52 Week High
- ADPT $15.94
- GLPG $37.78
- Technical
- Relative Strength Index (RSI)
- ADPT 66.13
- GLPG 51.05
- Support Level
- ADPT $14.11
- GLPG $33.58
- Resistance Level
- ADPT $15.26
- GLPG $34.80
- Average True Range (ATR)
- ADPT 0.73
- GLPG 0.85
- MACD
- ADPT 0.12
- GLPG -0.15
- Stochastic Oscillator
- ADPT 87.90
- GLPG 29.94
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.